JP2012501332A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2012501332A5 JP2012501332A5 JP2011525134A JP2011525134A JP2012501332A5 JP 2012501332 A5 JP2012501332 A5 JP 2012501332A5 JP 2011525134 A JP2011525134 A JP 2011525134A JP 2011525134 A JP2011525134 A JP 2011525134A JP 2012501332 A5 JP2012501332 A5 JP 2012501332A5
- Authority
- JP
- Japan
- Prior art keywords
- antibody
- antigen
- binding fragment
- lyophilized
- seq
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 239000000427 antigen Substances 0.000 claims description 35
- 102000036639 antigens Human genes 0.000 claims description 35
- 108091007433 antigens Proteins 0.000 claims description 35
- 239000012634 fragment Substances 0.000 claims description 35
- 102000011718 Interleukin-23 Subunit p19 Human genes 0.000 claims description 15
- 108010076561 Interleukin-23 Subunit p19 Proteins 0.000 claims description 15
- 239000012931 lyophilized formulation Substances 0.000 claims description 13
- CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 claims description 8
- 229930006000 Sucrose Natural products 0.000 claims description 8
- 239000008194 pharmaceutical composition Substances 0.000 claims description 8
- 239000000244 polyoxyethylene sorbitan monooleate Substances 0.000 claims description 8
- 235000010482 polyoxyethylene sorbitan monooleate Nutrition 0.000 claims description 8
- 229920000053 polysorbate 80 Polymers 0.000 claims description 8
- 229940068968 polysorbate 80 Drugs 0.000 claims description 8
- 238000002360 preparation method Methods 0.000 claims description 8
- 239000005720 sucrose Substances 0.000 claims description 8
- 239000007864 aqueous solution Substances 0.000 claims description 6
- 239000007979 citrate buffer Substances 0.000 claims description 4
- 238000009472 formulation Methods 0.000 claims description 4
- 239000000203 mixture Substances 0.000 claims description 4
- 239000000243 solution Substances 0.000 claims description 4
- 239000001509 sodium citrate Substances 0.000 claims description 2
- NLJMYIDDQXHKNR-UHFFFAOYSA-K sodium citrate Chemical compound O.O.[Na+].[Na+].[Na+].[O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O NLJMYIDDQXHKNR-UHFFFAOYSA-K 0.000 claims description 2
- 239000003814 drug Substances 0.000 claims 1
- 229940079593 drug Drugs 0.000 claims 1
- 230000008014 freezing Effects 0.000 claims 1
- 238000007710 freezing Methods 0.000 claims 1
- 239000000825 pharmaceutical preparation Substances 0.000 description 3
- 239000003085 diluting agent Substances 0.000 description 1
- 238000004108 freeze drying Methods 0.000 description 1
- 239000011521 glass Substances 0.000 description 1
- 238000002347 injection Methods 0.000 description 1
- 239000007924 injection Substances 0.000 description 1
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US9232608P | 2008-08-27 | 2008-08-27 | |
| US61/092,326 | 2008-08-27 | ||
| PCT/US2009/054842 WO2010027766A1 (en) | 2008-08-27 | 2009-08-25 | Lyophilized formulatons of engineered anti-il-23p19 antibodies |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2015184258A Division JP2016028086A (ja) | 2008-08-27 | 2015-09-17 | 操作された抗ＩＬ−２３ｐ１９抗体の凍結乾燥製剤 |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2012501332A JP2012501332A (ja) | 2012-01-19 |
| JP2012501332A5 true JP2012501332A5 (cg-RX-API-DMAC7.html) | 2012-10-04 |
| JP5931442B2 JP5931442B2 (ja) | 2016-06-08 |
Family
ID=41495339
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2011525134A Active JP5931442B2 (ja) | 2008-08-27 | 2009-08-25 | 操作された抗ＩＬ−２３ｐ１９抗体の凍結乾燥製剤 |
| JP2015184258A Pending JP2016028086A (ja) | 2008-08-27 | 2015-09-17 | 操作された抗ＩＬ−２３ｐ１９抗体の凍結乾燥製剤 |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2015184258A Pending JP2016028086A (ja) | 2008-08-27 | 2015-09-17 | 操作された抗ＩＬ−２３ｐ１９抗体の凍結乾燥製剤 |
Country Status (8)
| Country | Link |
|---|---|
| US (1) | US8263748B2 (cg-RX-API-DMAC7.html) |
| EP (1) | EP2331078B1 (cg-RX-API-DMAC7.html) |
| JP (2) | JP5931442B2 (cg-RX-API-DMAC7.html) |
| CN (1) | CN102202655B (cg-RX-API-DMAC7.html) |
| AU (1) | AU2009288419B2 (cg-RX-API-DMAC7.html) |
| CA (1) | CA2734919C (cg-RX-API-DMAC7.html) |
| MX (1) | MX2011002159A (cg-RX-API-DMAC7.html) |
| WO (1) | WO2010027766A1 (cg-RX-API-DMAC7.html) |
Families Citing this family (31)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JO3244B1 (ar) | 2009-10-26 | 2018-03-08 | Amgen Inc | بروتينات ربط مستضادات il – 23 البشرية |
| JP5972871B2 (ja) | 2010-07-20 | 2016-08-17 | テバ・ファーマシューティカルズ・オーストラリア・ピーティワイ・リミテッド | 抗ｉｌ−２３ヘテロ二量体特異的抗体 |
| AP3953A (en) | 2010-11-04 | 2016-12-22 | Boehringer Ingelheim Int | Anti-IL-23 antibodies |
| JP6431372B2 (ja) | 2011-10-25 | 2018-11-28 | プロシーナ バイオサイエンシーズ リミテッド | 抗体製剤および方法 |
| US10451621B2 (en) | 2011-12-31 | 2019-10-22 | Allergan, Inc. | Highly sensitive cell-based assay to detect the presence of active botulinum neurotoxin serotype-A |
| MX370199B (es) * | 2012-02-16 | 2019-12-05 | Santarus Inc | Composiciones farmaceuticas de anticuerpo anti-antigeno muy tardio (cd49a). |
| JP6293120B2 (ja) | 2012-05-03 | 2018-03-14 | ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング | 抗ＩＬ−２３ｐ１９抗体 |
| CZ304514B6 (cs) | 2012-11-23 | 2014-06-11 | Biotechnologický Ústav Av Čr, V.V.I. | Polypeptidy pro léčbu autoimunitních chorob založenou na blokaci receptoru pro lidský cytokin IL-23 |
| UA117466C2 (uk) * | 2012-12-13 | 2018-08-10 | Мерк Шарп Енд Доме Корп. | СТАБІЛЬНИЙ СКЛАД У ВИГЛЯДІ РОЗЧИНУ АНТИТІЛА ДО IL-23p19 |
| EP2968488A1 (en) | 2013-03-15 | 2016-01-20 | Amgen Inc. | Methods for treating psoriasis using an anti-il-23 antibody |
| AU2014228553B2 (en) | 2013-03-15 | 2019-01-24 | Amgen Inc. | Methods for treating Crohn's disease using an anti-IL23 antibody |
| JP2017524359A (ja) | 2014-07-24 | 2017-08-31 | ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング | Ｉｌ−２３ａ関連疾患の処置に有用なバイオマーカー |
| TWI711629B (zh) | 2014-09-03 | 2020-12-01 | 德商包林格因蓋爾漢國際股份有限公司 | 靶向IL-23A與TNF-α之化合物及其用途 |
| AR102417A1 (es) | 2014-11-05 | 2017-03-01 | Lilly Co Eli | Anticuerpos biespecíficos anti-tnf- / anti-il-23 |
| EA201791734A1 (ru) | 2015-02-04 | 2018-01-31 | Бёрингер Ингельхайм Интернациональ Гмбх | Способ лечения воспалительных заболеваний |
| MX2018003376A (es) | 2015-09-17 | 2018-08-15 | Amgen Inc | Prediccion de la respuesta clinica a antagonistas de il23 mediante el uso de biomarcadores de la via de il23. |
| JP2018538249A (ja) | 2015-11-04 | 2018-12-27 | アストラゼネカ アクチボラグ | 好酸球性疾患における好酸球標的化治療薬に対する臨床応答の予測変数としてのジペプチジルペプチダーゼ−４およびペリオスチン |
| AU2016379157A1 (en) | 2015-12-22 | 2018-06-21 | Amgen Inc. | CCL20 as a predictor of clinical response to IL23-antagonists |
| AU2017210313B2 (en) | 2016-01-22 | 2018-07-26 | Baxter Healthcare Sa | Sterile solutions product bag |
| NZ743477A (en) | 2016-01-22 | 2019-03-29 | Baxter Healthcare Sa | Method and machine for producing sterile solution product bags |
| CA3048381A1 (en) | 2016-12-28 | 2018-07-05 | Jcr Pharmaceuticals Co., Ltd. | Lyophilized preparation |
| JP7382232B2 (ja) | 2017-05-02 | 2023-11-16 | メルク・シャープ・アンド・ドーム・エルエルシー | 抗ｌａｇ３抗体の製剤および抗ｌａｇ３抗体と抗ｐｄ－１抗体との共製剤 |
| JOP20190260A1 (ar) | 2017-05-02 | 2019-10-31 | Merck Sharp & Dohme | صيغ ثابتة لأجسام مضادة لمستقبل الموت المبرمج 1 (pd-1) وطرق استخدامها |
| CA3105598A1 (en) | 2018-07-13 | 2020-01-16 | Carl GOMMOLL | Treating ulcerative colitis with brazikumab |
| MX2021005394A (es) | 2018-11-07 | 2021-07-06 | Merck Sharp & Dohme Llc | Co-formulaciones de anticuerpos anti-gen de activacion de linfocitos 3 (anti-lag3) y anticuerpos anti-muerte programada-1 (anti-pd-1). |
| US12098195B2 (en) | 2018-11-27 | 2024-09-24 | Innovent Biologics (Suzhou) Co., Ltd. | Anti-IL-23p19 antibody and use thereof in treating diseases |
| JOP20210229A1 (ar) | 2019-02-18 | 2023-01-30 | Lilly Co Eli | صيغة جسم مضاد علاجي |
| US20220298233A1 (en) * | 2019-04-15 | 2022-09-22 | Sun Pharmaceutical Industries Limited | Methods for Treatment of Subjects with Psoriatic Arthritis |
| TW202535466A (zh) * | 2019-09-09 | 2025-09-16 | 德商百靈佳殷格翰國際股份有限公司 | 抗-il-23p19抗體調配物 |
| GB202107153D0 (en) * | 2021-05-19 | 2021-06-30 | UCB Biopharma SRL | Method for filling vials containing liquid drug products |
| CN115785267B (zh) * | 2021-09-10 | 2023-12-15 | 三优生物医药(上海)有限公司 | 一种靶向IL-23p19的抗体或其抗原结合片段及其应用 |
Family Cites Families (21)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5859205A (en) * | 1989-12-21 | 1999-01-12 | Celltech Limited | Humanised antibodies |
| US6685940B2 (en) * | 1995-07-27 | 2004-02-03 | Genentech, Inc. | Protein formulation |
| US6267958B1 (en) * | 1995-07-27 | 2001-07-31 | Genentech, Inc. | Protein formulation |
| US6991790B1 (en) * | 1997-06-13 | 2006-01-31 | Genentech, Inc. | Antibody formulation |
| US6171586B1 (en) * | 1997-06-13 | 2001-01-09 | Genentech, Inc. | Antibody formulation |
| ATE365052T1 (de) * | 1999-02-22 | 2007-07-15 | Univ Connecticut | Neue albuminfreie faktor viii formulierungen |
| ES2338218T3 (es) * | 2001-07-25 | 2010-05-05 | Facet Biotech Corporation | Formulacion farmacologica liofilizada estable de anticuerpos igg daclizumab. |
| HUE051878T2 (hu) | 2003-02-10 | 2021-03-29 | Biogen Ma Inc | Immunglobulin készítmény és annak elõállítási módszere |
| MX369959B (es) * | 2003-05-14 | 2019-11-27 | Immunogen Inc | Composicion de farmaco conjugado. |
| ATE518888T1 (de) * | 2003-10-09 | 2011-08-15 | Chugai Pharmaceutical Co Ltd | Stabilisierte lösung mit hoher igm-konzentration |
| BRPI0611800A2 (pt) * | 2005-06-15 | 2008-12-09 | Schering Corp | formulaÇço estÁvel de anticorpo |
| PL1896073T3 (pl) * | 2005-06-30 | 2013-08-30 | Janssen Biotech Inc | Przeciwciała anty-IL-23, kompozycje, sposoby i zastosowania |
| PL1937721T3 (pl) | 2005-08-25 | 2010-12-31 | Lilly Co Eli | Przeciwciała anty-IL23 |
| HRP20170444T1 (hr) * | 2005-08-31 | 2017-05-19 | Merck Sharp & Dohme Corp. | Projektirana anti-il-23 antitijela |
| DK3219328T3 (da) * | 2005-12-29 | 2020-07-13 | Janssen Biotech Inc | Humane anti-il-23-antistoffer, sammensætninger, fremgangsmåder og anvendelser |
| CA2644906C (en) * | 2006-03-06 | 2016-05-10 | Medimmune, Inc. | Humanized anti-cd22 antibodies and their use in treatment of oncology, transplantation and autoimmune disease |
| CA2655372A1 (en) | 2006-06-13 | 2007-12-21 | Zymogenetics, Inc. | Il-17 and il-23 antagonists and methods of using the same |
| WO2008088823A2 (en) * | 2007-01-16 | 2008-07-24 | Abbott Laboratories | Methods for treating psoriasis |
| EP2064242A1 (en) | 2007-02-23 | 2009-06-03 | Schering Corporation | Engineered anti-il-23p19 antibodies |
| MX2009009079A (es) | 2007-02-23 | 2009-08-31 | Schering Corp | Anticuerpos anti-il-23p19 de ingenieria. |
| AR068723A1 (es) | 2007-10-05 | 2009-12-02 | Glaxo Group Ltd | Proteina que se une a antigenos que se une a il-23 humana y sus usos |
-
2009
- 2009-08-25 US US13/061,076 patent/US8263748B2/en active Active
- 2009-08-25 AU AU2009288419A patent/AU2009288419B2/en active Active
- 2009-08-25 CN CN2009801428023A patent/CN102202655B/zh active Active
- 2009-08-25 MX MX2011002159A patent/MX2011002159A/es active IP Right Grant
- 2009-08-25 WO PCT/US2009/054842 patent/WO2010027766A1/en not_active Ceased
- 2009-08-25 CA CA2734919A patent/CA2734919C/en active Active
- 2009-08-25 JP JP2011525134A patent/JP5931442B2/ja active Active
- 2009-08-25 EP EP09791868A patent/EP2331078B1/en active Active
-
2015
- 2015-09-17 JP JP2015184258A patent/JP2016028086A/ja active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2012501332A5 (cg-RX-API-DMAC7.html) | ||
| Tai et al. | A recombinant receptor-binding domain of MERS-CoV in trimeric form protects human dipeptidyl peptidase 4 (hDPP4) transgenic mice from MERS-CoV infection | |
| JP7528249B2 (ja) | Ｃｏｖｉｄ－１９に対する抗原特異的免疫療法、融合タンパク質、およびその使用方法 | |
| Sun et al. | Thermal stability of self-assembled peptide vaccine materials | |
| Huleatt et al. | A West Nile virus recombinant protein vaccine that coactivates innate and adaptive immunity | |
| US9861696B2 (en) | Monoclonal antibodies for Ebola and Marburg viruses | |
| JP5960120B2 (ja) | ウイルス粒子の安定化 | |
| US20230181730A1 (en) | Methods of treating infections | |
| BR112021004193A2 (pt) | vacinas pneumocócicas multivalentes | |
| JP2016534052A5 (cg-RX-API-DMAC7.html) | ||
| IL274846B2 (en) | Formulation for anti-alpha 4 antibody in cell 7 | |
| Nguyen et al. | The respiratory syncytial virus G protein conserved domain induces a persistent and protective antibody response in rodents | |
| US11406704B2 (en) | Adjuvants | |
| KR20130114210A (ko) | 스타필로코커스 아우레우스 항원의 안정한 면역원성 조성물 | |
| JPS58213723A (ja) | 口蹄疫ウイルス抗原の特異性を有する小型ペプチド | |
| Stinson et al. | Thin silk fibroin films as a dried format for temperature stabilization of inactivated polio vaccine | |
| Demircan et al. | Biotin functionalized self‐assembled peptide nanofiber as an adjuvant for immunomodulatory response | |
| KR20210088535A (ko) | 폐렴구균 융합 단백질 백신 | |
| TWI615158B (zh) | 多肽之調配物 | |
| Gamvrellis et al. | Characterisation of local immune responses induced by a novel nano-particle based carrier-adjuvant in sheep | |
| US20230210980A1 (en) | Chimeric adenoviral vectors | |
| KR20230135598A (ko) | 안정한 코로나바이러스 단백질 및 그의 백신 조성물 | |
| US20230233667A1 (en) | Coronavirus vaccine | |
| Zagorski et al. | Peptide Nanoarray Scaffold Vaccine for SARS-COV-2 and Its Variants of Concerns | |
| US10829542B2 (en) | Methods for affecting Salmonella infections |